188 related articles for article (PubMed ID: 32525541)
21. Eosinophilia in Hematologic Disorders.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
[TBL] [Abstract][Full Text] [Related]
22. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract][Full Text] [Related]
23. [Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1].
Fan XS; Wang SA
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):779-83. PubMed ID: 23302345
[No Abstract] [Full Text] [Related]
24. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
25. Eosinophilic myeloid neoplasms.
Noel P; Mesa RA
Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
[TBL] [Abstract][Full Text] [Related]
26. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
Bain BJ
Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
[TBL] [Abstract][Full Text] [Related]
27. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
28. Eosinophilia: secondary, clonal and idiopathic.
Tefferi A; Patnaik MM; Pardanani A
Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
[TBL] [Abstract][Full Text] [Related]
29. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.
Bain BJ
Haematologica; 2010 May; 95(5):696-8. PubMed ID: 20442440
[No Abstract] [Full Text] [Related]
30. A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience.
Fang H; Ketterling RP; Hanson CA; Pardanani A; Kurtin PJ; Chen D; Greipp PT; Howard MT; King RL; Van Dyke DL; Reichard KK
Am J Clin Pathol; 2018 Oct; 150(5):421-431. PubMed ID: 30032299
[TBL] [Abstract][Full Text] [Related]
31. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
32. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Metzgeroth G; Steiner L; Naumann N; Lübke J; Kreil S; Fabarius A; Haferlach C; Haferlach T; Hofmann WK; Cross NCP; Schwaab J; Reiter A
Leukemia; 2023 Sep; 37(9):1860-1867. PubMed ID: 37454239
[TBL] [Abstract][Full Text] [Related]
33. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J; Cross NC; Gilliland DG
Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
[TBL] [Abstract][Full Text] [Related]
34. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.
Vega F; Medeiros LJ; Bueso-Ramos CE; Arboleda P; Miranda RN
Am J Clin Pathol; 2015 Sep; 144(3):377-92. PubMed ID: 26276769
[TBL] [Abstract][Full Text] [Related]
35. Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.
Stella S; Massimino M; Manzella L; Pennisi MS; Tirrò E; Romano C; Vitale SR; Puma A; Tomarchio C; Gregorio SD; Palumbo GA; Vigneri P
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418988
[TBL] [Abstract][Full Text] [Related]
36. A novel activating JAK1 mutation in chronic eosinophilic leukemia.
Shomali W; Damnernsawad A; Theparee T; Sampson D; Morrow Q; Yang F; Fernandez-Pol S; Press R; Zehnder J; Tyner JW; Gotlib J
Blood Adv; 2021 Sep; 5(18):3581-3586. PubMed ID: 34496019
[TBL] [Abstract][Full Text] [Related]
37. The Diagnostic Work-Up of Hypereosinophilia.
Wang SA
Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056
[TBL] [Abstract][Full Text] [Related]
38. Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children.
Berking AC; Flaadt T; Behrens YL; Yoshimi A; Leipold A; Holzer U; Lang P; Quintanilla-Martinez L; Schlegelberger B; Reiter A; Niemeyer C; Strahm B; Göhring G
Cancer Genet; 2023 Apr; 272-273():29-34. PubMed ID: 36657267
[TBL] [Abstract][Full Text] [Related]
39. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
40. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]